Sigma Healthcare (ASX:SIG) raised its fiscal 2025 normalized earnings before interest and tax guidance to a range of AU$64 to AU$70 million, up from the previous guidance of AU$50 to AU$60 million, according to a Friday filing with the Australian bourse.
The increase follows strong performance, particularly from the Chemist Warehouse supply contract that started on July 1, 2024, the filing said.
Statutory net profit after tax for the fiscal year will be "significantly" impacted by non-recurring merger costs, including changes to performance rights, subject to audit completion, the filing added.
The company's shares rose past 5% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。